Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions.
Novartis AG, which brought the first approved chimeric antigen receptor T-cell (CAR-T) therapy Kymriah (tisagenlecleucel) to market, now is...








